Renal Cell Cancer (RCC): Making a Plethora of Drugs Understandable
EVENT DETAILS AND REGISTRATION
Date:December 01, 2016
Time: 05:30 PM - 08:00 PM (PT)
Location:Visitor Center, City of Hope, Duarte, CA
Presenters:Clayton S. Lau, M.D. • Director, Urologic Oncology and Robotic Surgery Fellowship • Director, Prostate Cancer Program • Head, Retroperitoneal Surgery • Associate Clinical Professor, Department of Surgery • Director, Urology & Urologic Oncology Fe
- Discuss the options for operative and minimally invasive surgical management of localized and metastatic renal cell cancer (mRCC).
- Review the molecular genetics and biology of renal cell cancer (RCC) and integrate predictive/prognostic markers into treatment decision-making for patients who have mRCC.
- Analyze emerging clinical data evaluating the use of systemic, targeted, and immunomodulatory therapies for mRCC, either sequentially and/or in combination, and in the first-line and second-line settings.
- Profile and discuss common adverse effects associated with agents used to treat mRCC and develop strategies for managing these toxicities.
- Identify and implement strategies to individualize therapy and optimize therapeutic outcomes for the patient with mRCC.
Who should attend:Medical Oncologists, Surgeons, Radiation Oncologists, Urologists, Internists, and other allied health care professionals who treat patients with renal cell cancer.
CME credits:1.5 - AMA PRA Category 1 CreditTM
R.S.V.P.: Click here to register